PPAR Agonists Reduce Pruritus in PBC: Meta-Analysis of 660 Patients
New drugs ease itch for patients whose current treatment fails
This systematic review and meta-analysis of 660 patients with primary biliary cholangitis and inadequate response to UDCA found that PPAR ag…
A review of six hundred sixty patients found new medicines significantly reduced itch scores in people with primary biliary cholangitis who …
Hepatic steatosis prevalence and impact in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis
Fatty liver makes autoimmune hepatitis and PBC worse, but not PSC.
This systematic review and meta-analysis of 19,898 patients with autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing c…
A large review found fatty liver is common in autoimmune liver diseases and makes outcomes worse for some patients, but not others.
Narrative review on T cell subsets in primary biliary cholangitis
New Liver Drug Targets Hidden Immune Cells
This narrative review synthesizes evidence on T cell subsets in primary biliary cholangitis. It finds associations between T cell imbalances…
Stopping the wrong immune cells could finally stop liver disease for those who do not respond to standard care.
Seladelpar shows improved composite endpoint and ALP reduction in PBC with compensated cirrhosis.
New Drug Helps Liver Disease Patients With Cirrhosis
A phase 3 RCT program (RESPONSE and ASSURE studies) in patients with primary biliary cholangitis and compensated cirrhosis found seladelpar …
A new drug lowers liver stress markers in patients with cirrhosis, offering hope where older medicines often failed to stop disease progress…